NR1H4 and metabolic dysfunction-associated steatohepatitis: Based on these positive data, a variety of FXR agonists have been developed for NASH treatment in an attempt to enhance efficacy and reduce side effects using bile acids, steroidal nonbile acids, or nonsteroidal scaffolds [14,15].